These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
425 related articles for article (PubMed ID: 15325792)
1. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo. Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792 [TBL] [Abstract][Full Text] [Related]
2. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616 [TBL] [Abstract][Full Text] [Related]
3. Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis. Kawakami K; Kinjo Y; Yara S; Uezu K; Koguchi Y; Tohyama M; Azuma M; Takeda K; Akira S; Saito A Infect Immun; 2001 Nov; 69(11):6643-50. PubMed ID: 11598033 [TBL] [Abstract][Full Text] [Related]
4. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. Tomura M; Yu WG; Ahn HJ; Yamashita M; Yang YF; Ono S; Hamaoka T; Kawano T; Taniguchi M; Koezuka Y; Fujiwara H J Immunol; 1999 Jul; 163(1):93-101. PubMed ID: 10384104 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment. Habu Y; Uchida T; Inui T; Nakashima H; Fukasawa M; Seki S Immunology; 2004 Sep; 113(1):35-43. PubMed ID: 15312134 [TBL] [Abstract][Full Text] [Related]
6. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711 [TBL] [Abstract][Full Text] [Related]
8. Effects of cyclosporin A on the activation of natural killer T cells induced by alpha-galactosylceramide. Kajiwara T; Tomita Y; Okano S; Iwai T; Yasunami Y; Yoshikai Y; Nomoto K; Yasui H; Tominaga R Transplantation; 2007 Jan; 83(2):184-92. PubMed ID: 17264815 [TBL] [Abstract][Full Text] [Related]
9. alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Kitamura H; Ohta A; Sekimoto M; Sato M; Iwakabe K; Nakui M; Yahata T; Meng H; Koda T; Nishimura S; Kawano T; Taniguchi M; Nishimura T Cell Immunol; 2000 Jan; 199(1):37-42. PubMed ID: 10675273 [TBL] [Abstract][Full Text] [Related]
10. Mice deficient in Vbeta8+NKT cells are resistant to experimental hepatitis but are partially susceptible to generalised Shwartzman reaction. Habu Y; Shinomiya N; Kinoshita M; Matsumoto A; Kawabata T; Seki S Clin Exp Med; 2007 Mar; 7(1):30-8. PubMed ID: 17380303 [TBL] [Abstract][Full Text] [Related]
11. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261 [TBL] [Abstract][Full Text] [Related]
12. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891 [TBL] [Abstract][Full Text] [Related]
13. Cytokine production and migration of in vitro-expanded NK1.1(-) invariant Valpha14 natural killer T (Valpha14i NKT) cells using alpha-galactosylceramide and IL-2. Ikarashi Y; Iizuka A; Heike Y; Yoshida M; Takaue Y; Wakasugi H Immunol Lett; 2005 Nov; 101(2):160-7. PubMed ID: 16054231 [TBL] [Abstract][Full Text] [Related]
14. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710 [TBL] [Abstract][Full Text] [Related]
15. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide]. Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267 [TBL] [Abstract][Full Text] [Related]
16. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide. Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815 [TBL] [Abstract][Full Text] [Related]
17. Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors. Biburger M; Tiegs G J Leukoc Biol; 2008 Jul; 84(1):264-79. PubMed ID: 18407967 [TBL] [Abstract][Full Text] [Related]
18. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide. Tulley JM; Palmer JL; Gamelli RL; Faunce DE Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934 [TBL] [Abstract][Full Text] [Related]
19. Role of γδ T cells in α-galactosylceramide-mediated immunity. Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194 [TBL] [Abstract][Full Text] [Related]
20. IL-21 enhances dendritic cell ability to induce interferon-gamma production by natural killer T cells. Maeda M; Yanagawa Y; Iwabuchi K; Minami K; Nakamaru Y; Takagi D; Fukuda S; Onoé K Immunobiology; 2007; 212(7):537-47. PubMed ID: 17678711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]